Embecta (MEX:EMBC) Moat Score: 5/10 (As of Jun. 30, 2026)


MEX:EMBC Embecta Corp MEX:EMBC
53 GF Score
Price MXN497.96
GF Value MXN1,910.60
! 6 Warning Signs
View Full Analysis

What is Embecta Moat Score?

Embecta MEX:EMBC 53 Moat Score is 5 as of Jun. 30, 2026. GuruFocus rates MEX:EMBC with a GF Score™ of 53/100 and a GF Value™ of MXN1,910.60. The stock has 6 warning signs investors should review. Among 846 Medical Devices & Instruments companies, Embecta ranks better than 91.25% on this metric.

Embecta has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

Embecta has Narrow Moat: Embecta Corp has a solid narrow moat due to its strong brand strength and customer loyalty in the medical device sector. It benefits from moderate switching costs and some proprietary technology, but lacks significant regulatory barriers or network effects to elevate it to a wide moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Embecta might have Narrow Moat - Solid narrow moat.

Embecta  (MEX:EMBC) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Embecta Moat Score Related Terms

MEX:EMBC vs KRMD, SMTI, PDEX: Moat Score Comparison

For the Medical Instruments & Supplies subindustry, Embecta's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Embecta Moat Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Embecta's Moat Score distribution charts can be found below:

* The bar in red indicates where Embecta's Moat Score falls into.


MEX:EMBC
53GF Score
Embecta Corp MEX:EMBC
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
Embecta (MEX:EMBC) has a Moat Score of 5 as of Jun. 30, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Embecta ranks #74 out of 846 companies in the Medical Devices & Instruments industry, placing it in the top 8.7%.
Is Embecta's Moat Score too high?
Embecta's current Moat Score is 5. Based on the distribution chart, Embecta ranks #74 out of 846 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Embecta has a GF Score™ of 53/100, reflecting its overall financial health beyond just this single metric.
How does Embecta's Moat Score compare to KRMD and SMTI?
According to the Medical Devices & Instruments industry distribution chart, Embecta ranks #74 out of 846 companies for Moat Score. This places Embecta in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Devices & Instruments company?
A good Moat Score depends on the Medical Devices & Instruments industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Embecta's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Embecta stock overvalued right now?
Embecta (MEX:EMBC) has a current Moat Score of 5. The stock's GF Value™ is MXN1,910.60, compared to a current price of MXN497.96 — trading 73.9% below its estimated fair value. The current Moat Score is 5. Embecta's overall GF Score™ is 53/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Embecta (MEX:EMBC), the current Moat Score is 5 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Embecta (MEX:EMBC) Overvalued in 2026?

Based on GuruFocus' analysis, Embecta stock appears to be undervalued. The current stock price of MXN497.96 is trading 73.9% below its estimated GF Value™ of MXN1,910.60.

Key valuation signals for MEX:EMBC:

  • Moat Score: 5
  • GF Value™: MXN1,910.60 vs. price of MXN497.96 (73.9% below fair value)
  • GF Score™: 53/100 with 6 warning signs

No single metric tells the full story. See the MEX:EMBC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Embecta Business Description

Other Exchanges EMBC:USAJX7:Germany
Address 300 Kimball Drive, Suite 300, Parsippany, NJ, USA, 07054
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.
53GF Score

Get the complete analysis for MEX:EMBC

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN497.96
Price
MXN1,910.60
GF Value